Proteonomix, Inc. (PROT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerProteonomix, Inc. (PROT) trades at $0.0001. Proteonomix, Inc. is a biotechnology company focused on developing therapeutics utilizing human cells and their derivatives, with a product pipeline addressing anti-aging skincare, liver disease, and cardiac repair. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for PROT: PROT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Proteonomix, Inc. (PROT) Healthcare & Pipeline Overview
Proteonomix, Inc. is a biotechnology firm specializing in human cell and derivative-based therapeutics, offering products like anti-aging skin creams and investigational treatments for liver disease and cardiac repair. The company, incorporated in 1995, operates with a focus on proprietary protein matrices and stem cell technologies from its Hawthorne, New Jersey base.
What Is the Investment Thesis for PROT?
Proteonomix, Inc. operates within the dynamic biotechnology sector, focusing on the development of therapeutics utilizing human cells and their derivatives, a field with substantial long-term growth potential. The company's pipeline includes both commercialized anti-aging skincare products, Proteoderm and NC-138, which leverage proprietary protein matrices, and investigational therapies like UMK-121 for liver disease and StromaCel for cardiac repair post-myocardial infarction. These therapeutic candidates address significant medical needs, representing potential value drivers if they advance through clinical development and regulatory approval processes. The company's long operational history since its 1995 incorporation, coupled with its patented technology for anti-aging products, establishes a foundation for its intellectual property. However, the company currently exhibits a negative profit margin of -5322.3% and operates with a very small employee base of two, indicating a highly early-stage or R&D-intensive operational model. Future value creation is contingent on successful clinical progression, market adoption of its products, and effective management of its financial resources.
Based on FMP financials and quantitative analysis
PROT Key Highlights
Proteonomix, Inc. maintains a market capitalization of $0.00 billion, reflecting its micro-cap status within the biotechnology sector.
- The company reported a gross margin of 102.0%, indicating that its cost of goods sold is less than its revenue, which is unusual and may suggest specific accounting practices or revenue recognition related to its product sales.
- An operating profit margin of -5322.3% highlights significant operational losses relative to its revenue, underscoring the company's current unprofitability and R&D-heavy nature.
- The company's Beta is -54.99, an exceptionally low and negative value, which typically suggests an inverse relationship with market movements, though such an extreme figure often indicates low trading volume or specific market dynamics for OTC-listed stocks.
- Proteonomix, Inc. does not currently offer a dividend yield, consistent with many biotechnology companies that reinvest earnings into research and development or are not yet profitable.
Who Are PROT's Competitors?
PROT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PROT's Key Strengths?
Proprietary and patented protein matrix technology for anti-aging skincare products.
- Diverse product pipeline addressing both cosmetic (anti-aging) and significant medical needs (liver disease, cardiac repair).
- Focus on human cells and their derivatives, a high-potential area in biotechnology.
- Long operational history since incorporation in 1995.
What Are PROT's Weaknesses?
Extremely small operational scale with only two employees, potentially limiting R&D and commercialization capacity.
- Significant negative profit margin (-5322.3%), indicating substantial unprofitability.
- OTC market listing and unknown disclosure status, which can impact investor confidence and access to capital.
- Limited financial data publicly available, making comprehensive analysis challenging.
What Are the Key Risks for PROT?
Financial-distress signal — its Altman Z-Score of -6.74 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The company's significant negative profit margin of -5322.3% indicates substantial operational losses, raising concerns about long-term financial sustainability without significant revenue growth or cost control.
- Operating with only two employees presents a risk to the pace and scope of research, development, and commercialization efforts across its diverse product pipeline.
- The inherent challenges and high failure rates associated with biotechnology R&D, particularly for therapeutic candidates like UMK-121 and StromaCel, pose significant clinical and regulatory risks.
- As an 'OTC Other' listed company with an unknown disclosure status, Proteonomix, Inc. faces risks related to limited transparency, low liquidity, and difficulty in attracting institutional investment.
- Intense competition within both the anti-aging skincare market and the therapeutic development space could limit market penetration and future profitability for the company's products.
What Threats Does PROT Face?
- Intense competition from established pharmaceutical and biotechnology companies with greater resources.
- Significant regulatory hurdles and lengthy approval processes for therapeutic candidates like UMK-121 and StromaCel.
- Potential for clinical trial failures or lack of efficacy for pipeline products.
- Challenges in securing adequate funding for ongoing research, development, and potential commercialization.
- Market adoption risks for new and innovative therapies in competitive environments.
What Are PROT's Competitive Advantages?
- Proprietary and patented protein matrices used in anti-aging skincare products like Proteoderm and NC-138, providing intellectual property protection.
- Specialized focus on human cells and their derivatives for therapeutic development, indicating a niche expertise in biotechnology.
- Development of unique treatment approaches, such as mobilizing specific bone marrow stem cells for liver disease (UMK-121) and using donor stem cells for cardiac repair (StromaCel), which could offer clinical differentiation.
- Established presence since 1995, suggesting experience in navigating the biotechnology landscape, albeit with a small operational footprint.
What Does PROT Do?
Proteonomix, Inc., incorporated in 1995 and based in Hawthorne, New Jersey, is a biotechnology company dedicated to the development of therapeutics derived from human cells and their associated components. The company's strategic focus revolves around leveraging these biological insights to create innovative solutions across various medical and cosmetic fields. Initially known as National Stem Cell Holding, Inc., the company underwent a name change to Proteonomix, Inc. in August 2008, signaling its evolving corporate identity and scientific direction. Its product portfolio includes Proteoderm, an anti-aging skin cream formulated with a proprietary and patented matrix of proteins designed to reduce the appearance of wrinkles. Complementing this, NC-138 is another proprietary protein matrix product specifically developed to act on the skin, enhancing activities that contribute to wrinkle reduction. In the therapeutic space, Proteonomix is developing UMK-121, an investigational treatment for liver disease. This approach involves utilizing a combination of two or three approved drugs to mobilize specific bone marrow stem cells, aiming to address liver pathologies. Another key therapeutic candidate is StromaCel, designed for cardiac patients within two weeks of a myocardial infarction. StromaCel employs stem cells derived from donor bone marrow, administered via intravenous solution, with the objective of repairing damaged heart tissue. With a lean operational structure, the company maintains its headquarters in Hawthorne, US, and focuses its efforts on advancing these distinct product lines, aiming to capitalize on the therapeutic potential of human cells and their derivatives in areas of significant unmet need and market demand.
What Products and Services Does PROT Offer?
- Develops therapeutics based on human cells and their derivatives.
- Offers Proteoderm, an anti-aging skin cream with a proprietary and patented protein matrix to reduce wrinkles.
- Markets NC-138, another proprietary protein matrix designed to enhance skin activities that reduce wrinkles.
- Is developing UMK-121, a treatment for liver disease that mobilizes bone marrow stem cells using approved drugs.
- Is developing StromaCel, a treatment for cardiac patients post-myocardial infarction using donor bone marrow stem cells for heart tissue repair.
- Focuses on biotechnology solutions for both cosmetic and medical applications.
- Operates from Hawthorne, New Jersey, and was incorporated in 1995.
How Does PROT Make Money?
- Generates revenue through the sale of proprietary anti-aging skincare products, Proteoderm and NC-138, to consumers or distributors.
- Invests in research and development for its therapeutic pipeline, UMK-121 for liver disease and StromaCel for cardiac repair, with future revenue potential from product commercialization or licensing agreements.
- Leverages patented technology, specifically protein matrices, as a core asset in its product development and market differentiation strategy.
- Aims to address significant unmet medical needs in chronic diseases and post-acute care through its cell-based therapeutic candidates.
What Industry Does PROT Operate In?
Proteonomix, Inc. is positioned within the biotechnology industry, a sector characterized by intensive research and development aimed at creating novel biological products and technologies. The company's focus on human cells and their derivatives places it within the rapidly evolving fields of regenerative medicine, stem cell therapy, and advanced biopharmaceuticals. These segments are driven by significant unmet medical needs in areas such as chronic diseases, age-related conditions, and tissue repair. The competitive landscape is intense, featuring numerous established pharmaceutical giants and a multitude of smaller, innovative biotech firms vying for market share and intellectual property. Proteonomix's specific product lines, including anti-aging skincare and treatments for liver and cardiac diseases, target distinct market niches within this broader industry. Success in this environment often hinges on effective clinical development, regulatory navigation, and the ability to secure and defend intellectual property.
Who Are PROT's Key Customers?
- Consumers seeking anti-aging skincare solutions for products like Proteoderm and NC-138.
- Healthcare providers and hospitals, as potential future customers for UMK-121 (liver disease) and StromaCel (cardiac repair) upon regulatory approval.
- Patients suffering from liver diseases, who could benefit from UMK-121.
- Cardiac patients who have experienced a myocardial infarction, for whom StromaCel is being developed.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Proteonomix, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.74 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Proteonomix, Inc. stands at 38.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.4%, showing how much profit it generates from its asset base. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Proteonomix, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hawthorne, US. PROT has traded publicly since 1997.
PROT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PROT Latest News
No recent news available for PROT.
PROT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PROT.
Price Targets
Wall Street price target analysis for PROT.
PROT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PROT; grades run from A+ (80-100) to F (below 30).
Leadership: Michael Cohen
CEO
Michael Cohen leads Proteonomix, Inc., a biotechnology company focused on human cell and derivative-based therapeutics. His role involves overseeing the strategic direction and operational activities of the company, which maintains a lean structure with two employees. Given the company's focus on developing products ranging from anti-aging skin creams to treatments for liver and cardiac diseases, Mr. Cohen's background likely encompasses aspects of biotechnology, business development, and corporate management within the healthcare sector. His leadership is critical in navigating the complex R&D landscape and managing the company's diverse product pipeline.
Track Record: Under Michael Cohen's leadership, Proteonomix, Inc. continues to pursue the development of its key product candidates, including Proteoderm and NC-138 in anti-aging skincare, and the therapeutic programs UMK-121 for liver disease and StromaCel for cardiac repair. His tenure is marked by the ongoing efforts to advance these proprietary technologies and bring them to market. The company's sustained focus on human cell and derivative-based therapeutics reflects the strategic direction set during his management, aiming to capitalize on innovation in the biotechnology space.
PROT OTC Market Information
Proteonomix, Inc. trades on the 'OTC Other' tier of the OTC Markets Group. This tier is typically reserved for companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor the stringent requirements of major exchanges such as the NYSE or NASDAQ. Companies on 'OTC Other' often have limited public information, making them highly speculative and illiquid. Unlike exchanges that impose strict listing standards for financials, corporate governance, and minimum share prices, 'OTC Other' has minimal requirements, resulting in a less regulated trading environment. This tier is considered the lowest and most speculative of the OTC market segments.
- OTC Tier: OTC Other
- **Limited Transparency**: The 'Unknown' disclosure status means investors may not have access to timely or comprehensive financial and operational information, making informed investment decisions difficult.
- **Low Liquidity and Volatility**: Trading on the 'OTC Other' tier often results in extremely low trading volumes, wide bid-ask spreads, and significant price volatility, posing challenges for entry and exit strategies.
- **Lack of Regulatory Oversight**: Compared to major exchanges, the 'OTC Other' market has minimal regulatory requirements, which can expose investors to higher risks of fraud or manipulation.
- **Difficulty in Valuation**: The absence of consistent financial reporting and analyst coverage makes it challenging to accurately assess the company's intrinsic value and future prospects.
- **Limited Access to Capital**: The speculative nature and lack of transparency associated with 'OTC Other' companies can hinder their ability to raise capital through equity offerings, impacting growth and operational sustainability.
- Verify the company's current operational status and any recent business developments beyond the provided description.
- Investigate any available financial statements, even if unaudited, to assess revenue, expenses, and cash flow trends.
- Research management's background and track record, looking for any additional public information or past ventures.
- Examine the intellectual property claims (patents) for Proteoderm and NC-138 to confirm their validity and scope.
- Seek out any regulatory filings or news releases, however infrequent, to gauge progress on therapeutic candidates UMK-121 and StromaCel.
- Assess the competitive landscape for each product line to understand market positioning and potential challenges.
- Consult independent legal and financial advisors familiar with OTC markets before making any investment decisions.
- The company was incorporated in 1995, indicating a long-standing corporate existence.
- Specific product names and descriptions (Proteoderm, UMK-121, StromaCel, NC-138) are provided, detailing their intended applications.
- Mention of a 'proprietary and patented matrix of proteins' for anti-aging products suggests intellectual property assets.
- The company's stated focus on human cells and their derivatives aligns with a legitimate scientific area within biotechnology.
Proteonomix, Inc. Healthcare Stock: Key Questions Answered
What is Proteonomix, Inc.'s drug pipeline status?
Proteonomix, Inc. has two primary therapeutic candidates in its pipeline: UMK-121 and StromaCel. UMK-121 is being developed as a treatment for liver disease, utilizing a combination of approved drugs to mobilize specific bone marrow stem cells.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Detailed financial metrics beyond market cap, profit margin, gross margin, and beta are not available.
- Specific timelines, market sizes, and clinical trial phases for pipeline products are not provided in the source data.
- Information on management's detailed background and tenure is limited.
- The 'Unknown' disclosure status for OTC trading limits comprehensive analysis.